The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow,Elias Campo,Stefano Pileri,Nancy L. Harris,Harald Stein,Reiner Siebert,Ranjana H. Advani,Michele Ghielmini,Gilles Salles,Andrew D. Zelenetz,Elaine S. Jaffe +10 more
Reads0
Chats0
TLDR
The revision clarifies the diagnosis and management of lesions at the very early stages of lymphomagenesis, refines the diagnostic criteria for some entities, details the expanding genetic/molecular landscape of numerous lymphoid neoplasms and their clinical correlates, and refers to investigations leading to more targeted therapeutic strategies.About:
This article is published in Blood.The article was published on 2016-05-19 and is currently open access. It has received 5321 citations till now.read more
Citations
More filters
Journal ArticleDOI
Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways
Geffen Kleinstern,Huihuang Yan,Michelle A.T. Hildebrandt,Joseph Vijai,Sonja I. Berndt,Hervé Ghesquières,James McKay,Sophia S. Wang,Alexandra Nieters,Yuanqing Ye,Alain Monnereau,Angela Brooks-Wilson,Qing Lan,Mads Melbye,Rebecca D. Jackson,Lauren R. Teras,Mark P. Purdue,Claire M. Vajdic,Roel Vermeulen,Graham G. Giles,Graham G. Giles,Pierluigi Cocco,Brenda M. Birmann,Peter Kraft,Demetrius Albanes,Anne Zeleniuch-Jacquotte,Simon Crouch,Yawei Zhang,Vivekananda Sarangi,Yan W. Asmann,Kenneth Offit,Gilles Salles,Xifeng Wu,Karin E. Smedby,Christine F. Skibola,Susan L. Slager,Nathaniel Rothman,Stephen J. Chanock,James R. Cerhan +38 more
TL;DR: 2 loci at 3q13.33 and 3p24.1 provide additional evidence for the role of immune function in the etiology of DLBCL, the most common lymphoma subtype.
Journal ArticleDOI
Investigational drugs for the treatment of diffuse large B-cell lymphoma
TL;DR: This review illuminates those investigational drugs and cell therapies that are currently in early phase clinical trials for the treatment of DLBCL and suggests a focus on the optimal sequencing of the emergingDLBCL drugs is appropriate and necessary.
Journal ArticleDOI
Molecular Diagnosis of Felis catus Gammaherpesvirus 1 (FcaGHV1) Infection in Cats of Known Retrovirus Status with and without Lymphoma.
Alicia J. McLuckie,Vanessa R. Barrs,Scott A. Lindsay,Mahdis Aghazadeh,Cheryl Sangster,Julia A. Beatty +5 more
TL;DR: A history of fighting or roaming was identified as a novel epidemiological risk factor for FcaGHV1 detection, lending support to intercat aggression as a potential route of transmission and Prospective investigation of Fca GHV1 DNA detection as a prognostic marker in feline lymphoma is warranted.
Journal ArticleDOI
T- and NK-Cell Lymphomas and Systemic Lymphoproliferative Disorders and the Immunodeficiency Setting: 2015 SH/EAHP Workshop Report-Part 4.
Dita Gratzinger,Daphne de Jong,Elaine S. Jaffe,Amy Chadburn,John K.C. Chan,John R. Goodlad,Jonathan W. Said,Yasodha Natkunam +7 more
TL;DR: Systemic T- or NK-cell lymphomas are part of a spectrum of EBV+ T or NK lymphoproliferations and can present in the acquired immunodeficiency setting and must not be overdiagnosed as lymphoma.
Journal ArticleDOI
Association Between Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Risk and Polyurethane Breast Implants: Clinical Evidence and European Perspective
TL;DR: An overview on the use of polyurethane (PU) breast implants and the possible association with the risk of developing breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is presented, with a special look at the current situation in Europe.
References
More filters
Book
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
TL;DR: Thank you very much for reading who classification of tumours of haematopoietic and lymphoid tissues, and maybe you have knowledge that, people have look hundreds of times for their chosen readings like this, but end up in malicious downloads.
Journal ArticleDOI
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.
TL;DR: The criteria and significance of early or precursor lesions and the identification of certain lymphoid neoplasms largely associated with particular age groups, such as children and the elderly are addressed, and the issue of borderline categories having overlapping features with large B-cell lymphomas is reviewed.
Journal ArticleDOI
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Xose S. Puente,Magda Pinyol,Víctor Quesada,Laura Conde,Gonzalo R. Ordóñez,Neus Villamor,Geòrgia Escaramís,Pedro Jares,Sílvia Beà,Marcos González-Díaz,Laia Bassaganyas,Tycho Baumann,Manel Juan,Mónica López-Guerra,Dolors Colomer,Jose M. C. Tubio,Cristina López,Alba Navarro,Cristian Tornador,Marta Aymerich,María Rozman,Jesús M. Hernández,Diana A. Puente,José M.P. Freije,Gloria Velasco,Ana Gutiérrez-Fernández,Dolors Costa,Anna Carrió,Sara Guijarro,Anna Enjuanes,Lluis Hernández,Jordi Yagüe,Pilar Nicolás,Carlos M. Romeo-Casabona,Heinz Himmelbauer,Ester Castillo,Juliane C. Dohm,Silvia de Sanjosé,Miguel A. Piris,Enrique de Alava,Jesús F. San Miguel,Romina Royo,Josep Lluís Gelpí,David Torrents,Modesto Orozco,David G. Pisano,Alfonso Valencia,Roderic Guigó,Mònica Bayés,Simon Heath,Marta Gut,Peter Klatt,John Marshall,Keiran Raine,Lucy Stebbings,P. Andrew Futreal,Michael R. Stratton,Peter J. Campbell,Ivo Gut,Armando López-Guillermo,Xavier Estivill,Emili Montserrat,Carlos López-Otín,Elias Campo +63 more
TL;DR: The patterns of somatic mutation, supported by functional and clinical analyses, strongly indicate that the recurrent NOTCH1, MYD88 and XPO1 mutations are oncogenic changes that contribute to the clinical evolution of the disease.
Journal ArticleDOI
MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia
Steven P. Treon,Lian Xu,Guang Yang,Yangsheng Zhou,Xia Liu,Yang Cao,Patricia Sheehy,Robert Manning,Christopher J. Patterson,Christina K. Tripsas,Luca Arcaini,Geraldine S. Pinkus,Scott J. Rodig,Aliyah R. Sohani,Nancy L. Harris,Jason M. Laramie,Donald A Skifter,Stephen E Lincoln,Zachary R. Hunter +18 more
TL;DR: MYD88 L265P is a commonly recurring mutation in patients with Waldenström's macroglobulinemia that can be useful in differentiating WaldenStröm’s macrogalobulinesia and non-IgM LPL from B-cell disorders that have some of the same features.
Related Papers (5)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
Christine P. Hans,Dennis D. Weisenburger,Timothy C. Greiner,Randy D. Gascoyne,Jan Delabie,German Ott,H. Konrad Muller-Hermelink,Elias Campo,Rita M. Braziel,Elaine S. Jaffe,Zenggang Pan,Pedro Farinha,Lynette M. Smith,Brunangelo Falini,Alison H. Banham,Andreas Rosenwald,Louis M. Staudt,Joseph M. Connors,James O. Armitage,Wing C. Chan +19 more
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Ash A. Alizadeh,Michael B. Eisen,R. Eric Davis,Izidore S. Lossos,Andreas Rosenwald,Jennifer C. Boldrick,Hajeer Sabet,Truc Tran,Xin Yu,John Powell,Liming Yang,Gerald E. Marti,Troy Moore,James I. Hudson,Li-Sheng Lu,David B. Lewis,Robert Tibshirani,Gavin Sherlock,Wing C. Chan,Timothy C. Greiner,Dennis D. Weisenburger,James O. Armitage,Roger A. Warnke,Ronald Levy,Wyndham H. Wilson,M. R. Grever,John C. Byrd,David Botstein,Patrick O. Brown,Louis M. Staudt +29 more